ArticlePsychopharmacology2020
Assessing physiological dependence and withdrawal potential of mitragynine using schedule-controlled behaviour in rats.
Article in Psychopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans.Human psychopharmacology · 2022Pooled it
- Discovery of rhynchophylline and mitraphylline in two Thai Mitragyna species and the investigation of their biological activity via opioid gene expression analysis.Scientific reports · 2025Article
- Kratom safety and toxicology in the public health context: research needs to better inform regulation.Frontiers in pharmacology · 2024Review
- Kratom as a potential substance use disorder harm reduction agent.Frontiers in public health · 2024Review
- Kratom withdrawal: Discussions and conclusions of a scientific expert forum.Drug and alcohol dependence reports · 2023Article
- Physiological dependence to mitragynine indicated by a rapid cross-dependence procedure with heroin-dependent mice.Psychopharmacology · 2022Article
- Review
- Mitragynine improves cognitive performance in morphine-withdrawn rats.Psychopharmacology · 2022Article
- Pentylenetetrazol-like stimulus is not produced following naloxone-precipitated mitragynine withdrawal in rats.Psychopharmacology · 2021Article
- Kratom pharmacology: Clues from planarians exposed to mitragynine.Physiology & behavior · 2021Article
- Kratom Abuse Potential 2021: An Updated Eight Factor Analysis.Frontiers in pharmacology · 2021Review
- Methadone, Buprenorphine, and Clonidine Attenuate Mitragynine Withdrawal in Rats.Frontiers in pharmacology · 2021Article
- Evaluation of the rewarding effects of mitragynine and 7-hydroxymitragynine in an intracranial self-stimulation procedure in male and female rats.Drug and alcohol dependence · 2020Article
- An update on the clinical pharmacology of kratom: uses, abuse potential, and future considerations.Expert review of clinical pharmacologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
rationaleKratom is proposed to exhibit therapeutic potential as an opium substitute, but little is known about its dependence-producing profile, particularly of its main psychoactive compound, mitragynine (MG).
objectivesThis study examined the dependence-producing effects of MG using operant-scheduled behaviour in rats and investigated the potential therapeutic effect of MG by comparing effects to buprenorphine in morphine-dependent rats using the same schedule-controlled behavioural task.
methodsThe effects of acutely administered MG and morphine were determined in rats trained to respond under fixed-ratio (FR) 10 schedule of food reinforcement. Next, the rats were administered MG and morphine twice daily for 14 consecutive days to determine if physiological dependence would develop by examining cessation of drug treatment and following antagonist-precipitated withdrawal. The study then examined the effects of MG substitution to suppress naloxone-precipitated morphine withdrawal effects on scheduled responding.
resultsAcute doses of MG did not produce dose-related decreases on FR schedules of responding compared to morphine. Unlike morphine, MG-treated rats showed no suppression of response rates following cessation of MG treatment. However, withdrawal effects were evident for MG after precipitation by either naloxone or SR141716A (rimonabant), similar to morphine-treated rats. MG in higher doses (10 and 30 mg/kg) attenuated the naloxone-precipitated morphine withdrawal effects while smaller doses of buprenorphine (0.3 and 1.0 mg/kg) were necessary to alleviate these effects.
conclusionThe findings suggest that MG does not induce physiological dependence but can alleviate the physical symptoms associated with morphine withdrawal which represent the desired characteristics of novel pharmacotherapeutic interventions for managing opioid use disorder (OUD).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.